Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.

Current opinion in lipidology - 1 Dec 2010

Brouwers Martijn C G J, de Graaf Jacqueline, van Greevenbroek Marleen M J, Schaper Nicolaas, Stehouwer Coen D A, Stalenhoef Anton F H

Abstract excerpt

PURPOSE OF REVIEW: Familial combined hyperlipidemia (FCHL) and type 2 diabetes mellitus (T2DM) are prevalent entities that share many features of the metabolic syndrome. Recent findings suggest that FCHL and T2DM are less distinct than initially anticipated, which could offer new insights for their therapeutic approach. RECENT FINDINGS: Genetic association studies have provided evidence for a common genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholesterol, LDL
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Hyperlipidemia, Familial Combined

Share to Metabolic Syndrome

Share to Metformin

Share to Pioglitazone

Share to Thiazolidinediones

Source

Identifiers

PMID: 20739883
DOI: 10.1097/MOL.0b013e32833ea9ec

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus.PMID 20739883Read ↗

Familial combined hyperlipidemia: An overview of the underlying molecular mechanisms and therapeutic strategiesSemantic proximity Read ↗

Molecular mechanisms, prevalence, and molecular methods for familial combined hyperlipidemia disease: A reviewSemantic proximity Read ↗

Genetics of familial combined hyperlipidemia.Semantic proximity Read ↗

Combined hyperlipidemia: familial but not (usually) monogenic.Semantic proximity Read ↗

Genetics of familial combined hyperlipidemia and risk of coronary heart disease.Semantic proximity Read ↗

Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.Semantic proximity Read ↗

The genetics of familial combined hyperlipidaemia.Semantic proximity Read ↗

Unraveling the complex genetics of familial combined hyperlipidemia.Semantic proximity Read ↗

Genetic dissection of familial combined hyperlipidemia.Semantic proximity Read ↗

The Pro12A1a substitution in the peroxisome proliferator activated receptor gamma 2 is associated with an insulin-sensitive phenotype in families with familial combined hyperlipidemia and in nondiabetic elderly subjects with dyslipidemia.Semantic proximity Read ↗

[Familial combined hyperlipidemia].Semantic proximity Read ↗

Genetics of familial combined hyperlipidemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.